• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

PRAMIPEXOLE Drug Record

  • Summary
  • Interactions
  • Claims
  • PRAMIPEXOLE chembl:CHEMBL301265 Approved

    Alternate Names:

    U-98528E
    MIRAPEXIN
    PRAMIPEXOLE
    PIPEXUS
    NELIPRAX
    OPRYMEA
    SUD-919CL2Y
    PRAMIPEXOL
    SND-919CL2Y
    MIRAPEXIN®
    PRAMIPEXOLUM
    2,6-BENZOTHIAZOLEDIAMINE, 4,5,6,7-TETRAHYDRO-N(SUP 6)-PROPYL-, (S)-
    (S)-N  6-PROPYL-4,5,6,7-TETRAHYDRO-1,3-BENZOTHIAZOLE-2,6-DIAMINE
    SIFROL®
    (-)-PRAMIPEXOLE
    MIRAPEX®
    drugbank:00413
    chembl:CHEMBL301265
    pubchem.compound:119570
    chemidplus:104632-26-0
    rxcui:746741

    Drug Info:

    FDA Approval approved
    Drug Class Small Molecule
    Drug Indications antiparkinson agent
    Drug Class antidyskinetics
    Year of Approval 1997
    Drug Class antiparkinson agents
    (1 More Sources)

    Publications:

    Kvernmo et al., 2008, Receptor-binding and pharmacokinetic properties of dopaminergic agonists., Curr Top Med Chem
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Dooley M et al., 1998, Pramipexole. A review of its use in the management of early and advanced Parkinson's disease., Drugs Aging
    Mierau et al., 1995, Pramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4 receptors., Eur. J. Pharmacol.
    Piercey MF, 1998, Pharmacology of pramipexole, a dopamine D3-preferring agonist useful in treating Parkinson's disease., Clin Neuropharmacol
    Lam, 2000, Clinical pharmacology of dopamine agonists., Pharmacotherapy
    Chernoloz O et al., 2012, Long-term administration of the dopamine D3/2 receptor agonist pramipexole increases dopamine and serotonin neurotransmission in the male rat forebrain., J Psychiatry Neurosci
    Liu YZ et al., 2009, Association of the DRD2 and DRD3 polymorphisms with response to pramipexole in Parkinson's disease patients., Eur J Clin Pharmacol
    Merlino G et al., 2008, Clinical experience with pramipexole in the treatment of restless legs syndrome., Expert Opin Drug Metab Toxicol
  • PRAMIPEXOLE   DRD3

    Interaction Score: 3.8

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Novel drug target Established target
    Trial Name Mirapex

    PMIDs:
    18691132 10641988 11752352 19396436 22023785 9638397 9617505 18248314


    Sources:
    TdgClinicalTrial TEND PharmGKB TTD

  • PRAMIPEXOLE   DRD4

    Interaction Score: 3.43

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Trial Name Mirapex
    Novel drug target Established target

    PMIDs:
    18691132 11752352 9638397 7664822 9617505


    Sources:
    TdgClinicalTrial TEND

  • PRAMIPEXOLE   DRD2

    Interaction Score: 1.12

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Trial Name Mirapex
    Novel drug target Established target

    PMIDs:
    18691132 10641988 11752352 9638397 22023785 9617505


    Sources:
    TdgClinicalTrial TEND TTD

  • TdgClinicalTrial: PRAMIPEXOLE

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications antiparkinson agent
    Drug Class Small Molecule
    FDA Approval approved

    Publications:

  • TEND: PRAMIPEXOLE

    • Version: 01-August-2011

    Alternate Names:

    Drug Info:
    Drug Class antiparkinson agents
    Year of Approval 1997
    Drug Class antidyskinetics

    Publications:

  • PharmGKB: pramipexole

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Liu YZ et al., 2009, Association of the DRD2 and DRD3 polymorphisms with response to pramipexole in Parkinson's disease patients., Eur J Clin Pharmacol

  • TTD: Pramipexole

    • Version: 2020.06.01

    Alternate Names:
    D0G8NN TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL301265

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21